FDA warning: Increased MI, dyslipidemia with fosamprenavir – TheHeart.Org

posted on Dec 08 by in the Uncategorized category

FDA warning: Increased MI, dyslipidemia with fosamprenavir
TheHeart.Org
As well as regular monitoring of lipids before and after therapy, "other modifiable risk factors for cardiovascular disease (such as hypertension, diabetes, ...

and more »

Leave a Response

Get Adobe Flash playerPlugin by wpburn.com wordpress themes